JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walkenstein, S. S.
Right arrow Articles by Seifter, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walkenstein, S. S.
Right arrow Articles by Seifter, J.
Journal of Pharmacology And Experimental Therapeutics, Vol. 123, Issue 4, 254-258, 1958
Copyright © 1958 by American Society for Pharmacology and Experimental Therapeutics


THE EXCRETION AND DISTRIBUTION OF MEPROBAMATE AND ITS METABOLITES

Sidney S. Walkenstein 1, Cornelius M. Knebel 1, Joyce A. MacMullen 1, and Joseph Seifter 1

1 Wyeth Institute for Medical Research, Radnor, Pennsylvania

The absorption, excretion, distribution and metabolism of C14-labeled meprobamate, labeled in both carbamate groups, following oral and intraabdominal injection was studied in rats and dogs and of the nonlabeled drug after oral administration to humans. The drug was found to be readily absorbed from the gastrointestinal tract. Significant amounts of C14 began to appear in tile Urine within 30 minutes after an oral or intra-abdominal dose and by 24 hours most had been excreted. Feces contained less than 10 per cent of the dose. Blood levels of C14 reached a peak two hours after oral administration; 50 per cent of the amount present was unchanged meprobarnate. After adnlinistration of the drug to rats, lung, kidney and liver were found to have the highest levels of radioactivity.

The major metabolite, accounting for approximately 60 per cent of the dose in dogs, was isolated and identified as hydroxymeprobamate (2 - hydroxyrnethyl - 2 - n -propyl - 1 ,3 - propanediol dicarbamate). When this compound or the corresponding tricarbamate was administered to dogs no nleprobamate-like activity was observed.

A specific colorimetric method for determination of meprobarnate in plasma and urine based on the Brown modification of the Kober reaction was developed and is sensitive to concentrations as low as 5 microgm. per ml.

Submitted on May 5, 1958







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1958 by the American Society for Pharmacology and Experimental Therapeutics.